We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Products Stock Earnings on May 3: BDX, CAH & More
Read MoreHide Full Article
The first-quarter earnings season has taken center stage, with 267 members of the elite S&P 500 index having reported financial numbers so far.
Per the latest Earnings Preview, performances of these index participants indicate a 25.1% increase in total earnings on 10% higher revenues. The beat ratio has been impressive as well, with 76.8% companies surpassing bottom-line expectations and 73.8% beating the top-line mark.
The Medical sector (one of the 16 Zacks sectors) has put up a stellar show so far. The sector is expected to rise 12.9% on 7% revenue growth this earnings season.
What Awaits Medical Product Stocks?
The U.S. Medical Product industry has been gaining prominence of late, courtesy of increasing life-expectancy rates, aging population, changing market dynamics and use of technologically superior devices.
In fact, the industry is not dependent on just medical advancements solely. Nowadays, it relies on technological advancements in the microelectronics, telecommunications, instrumentation, biotechnology and software development industries as well.
In view of the above trends, investor sentiments have been solid toward Medical-Products companies. In fact, the industry has returned 12.2%, compared to the S&P 500’s rally of 10.7% in a year’s time. Further, the bipartisan suspension of the medical device tax has given a significant boost to the sector in the first quarter.
Meanwhile, MedTech bigwigs like Baxter International (BAX - Free Report) and Ecolab (ECL - Free Report) have reported upbeat first-quarter numbers. Both the companies have beaten the consensus estimate for both the counts, with a strong outlook for 2018.
Now, let’s take a look at four companies that are set to release results on May 3:
Becton. Dickinson and Company’s (BDX - Free Report) second-quarter fiscal 2018 results are likely to show strong outcome from the core BD Medical segment. Per management, steady growth across the sub-segments like Medication and Procedural Solutions and Pharmaceutical Systems are expected to be growth propellers. However, improvement in other segments should lead to improved results. (read more: Can BD Medical Drive Becton, Dickinson's Q2 Earnings?)
The Zacks Consensus Estimate for second-quarter earnings is pegged at $2.61, reflecting year-over-year growth of 13.5%.
BD has an Earnings ESP of +0.61% and a Zacks Rank #3 (Hold). Per the Zacks quantitative model, stocks with the advantageous combination of a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 and a positive Earnings ESP have higher chances of beating estimates. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Becton, Dickinson and Company Price and EPS Surprise
Cardinal Health, Inc.’s (CAH - Free Report) third-quarter fiscal 2018 results are likely to reflect a decline in the core Pharmaceutical segment, while growth across other segments is likely to make up for the decline partially. However, a raised guidance for 2018 buoys optimism.
Furthermore, the Medical segment is expected to post solid numbers, while the Medical Gloves unit results might witness softness in the quarter to be reported. (read more: What's in Store for Cardinal Health in Q3 Earnings?)
The Zacks Consensus Estimate for third-quarter earnings is pegged at $1.51, reflecting a decline of 1.3% year over year.
Teleflex Incorporated’s (TFX - Free Report) first-quarter 2018 earnings are expected to be strong on the back of the Vascular unit in North America. EMEA sales are also likely to be high.
The Zacks Consensus Estimate for earnings is pinned at $1.94, indicating year-over-year growth of 7.8%.
Teleflex has an earnings ESP of -0.20% and a Zacks Rank #3.
Abiomed Inc. is likely to see a strong fourth quarter of fiscal 2018 on the back of its flagship product line – Impella. Notably, in the last reported quarter, Impella revenues rose 30%, while internationally, Impella revenues increased a whopping 94%.
The plethora of regulatory approvals for Impella 5.5 and Impella CP is encouraging. Moreover, an increased guidance for 2018 buoys optimism. The Zacks Consensus Estimate for earnings is 64 cents, reflecting year-over-year growth of 93.9%.
The company has an Earnings ESP of 0.00% and a Zacks Rank #3.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Medical Products Stock Earnings on May 3: BDX, CAH & More
The first-quarter earnings season has taken center stage, with 267 members of the elite S&P 500 index having reported financial numbers so far.
Per the latest Earnings Preview, performances of these index participants indicate a 25.1% increase in total earnings on 10% higher revenues. The beat ratio has been impressive as well, with 76.8% companies surpassing bottom-line expectations and 73.8% beating the top-line mark.
The Medical sector (one of the 16 Zacks sectors) has put up a stellar show so far. The sector is expected to rise 12.9% on 7% revenue growth this earnings season.
What Awaits Medical Product Stocks?
The U.S. Medical Product industry has been gaining prominence of late, courtesy of increasing life-expectancy rates, aging population, changing market dynamics and use of technologically superior devices.
In fact, the industry is not dependent on just medical advancements solely. Nowadays, it relies on technological advancements in the microelectronics, telecommunications, instrumentation, biotechnology and software development industries as well.
In view of the above trends, investor sentiments have been solid toward Medical-Products companies. In fact, the industry has returned 12.2%, compared to the S&P 500’s rally of 10.7% in a year’s time. Further, the bipartisan suspension of the medical device tax has given a significant boost to the sector in the first quarter.
Meanwhile, MedTech bigwigs like Baxter International (BAX - Free Report) and Ecolab (ECL - Free Report) have reported upbeat first-quarter numbers. Both the companies have beaten the consensus estimate for both the counts, with a strong outlook for 2018.
Now, let’s take a look at four companies that are set to release results on May 3:
Becton. Dickinson and Company’s (BDX - Free Report) second-quarter fiscal 2018 results are likely to show strong outcome from the core BD Medical segment. Per management, steady growth across the sub-segments like Medication and Procedural Solutions and Pharmaceutical Systems are expected to be growth propellers. However, improvement in other segments should lead to improved results. (read more: Can BD Medical Drive Becton, Dickinson's Q2 Earnings?)
The Zacks Consensus Estimate for second-quarter earnings is pegged at $2.61, reflecting year-over-year growth of 13.5%.
BD has an Earnings ESP of +0.61% and a Zacks Rank #3 (Hold). Per the Zacks quantitative model, stocks with the advantageous combination of a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 and a positive Earnings ESP have higher chances of beating estimates. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote
Cardinal Health, Inc.’s (CAH - Free Report) third-quarter fiscal 2018 results are likely to reflect a decline in the core Pharmaceutical segment, while growth across other segments is likely to make up for the decline partially. However, a raised guidance for 2018 buoys optimism.
Furthermore, the Medical segment is expected to post solid numbers, while the Medical Gloves unit results might witness softness in the quarter to be reported. (read more: What's in Store for Cardinal Health in Q3 Earnings?)
The Zacks Consensus Estimate for third-quarter earnings is pegged at $1.51, reflecting a decline of 1.3% year over year.
The company has an Earnings ESP of +0.28% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health, Inc. Price and EPS Surprise
Cardinal Health, Inc. Price and EPS Surprise | Cardinal Health, Inc. Quote
Teleflex Incorporated’s (TFX - Free Report) first-quarter 2018 earnings are expected to be strong on the back of the Vascular unit in North America. EMEA sales are also likely to be high.
The Zacks Consensus Estimate for earnings is pinned at $1.94, indicating year-over-year growth of 7.8%.
Teleflex has an earnings ESP of -0.20% and a Zacks Rank #3.
Teleflex Incorporated Price and EPS Surprise
Teleflex Incorporated Price and EPS Surprise | Teleflex Incorporated Quote
Abiomed Inc. is likely to see a strong fourth quarter of fiscal 2018 on the back of its flagship product line – Impella. Notably, in the last reported quarter, Impella revenues rose 30%, while internationally, Impella revenues increased a whopping 94%.
The plethora of regulatory approvals for Impella 5.5 and Impella CP is encouraging. Moreover, an increased guidance for 2018 buoys optimism.
The Zacks Consensus Estimate for earnings is 64 cents, reflecting year-over-year growth of 93.9%.
The company has an Earnings ESP of 0.00% and a Zacks Rank #3.
ABIOMED, Inc. Price and EPS Surprise
ABIOMED, Inc. Price and EPS Surprise | ABIOMED, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>